Clinical Trial: A multicenter, single-arm, open-label clinical efficacy observation study of chidamide in combination with azacitidine, prednisone, cyclophosphamide, and thalidomide for the treatment of peripheral T-cell lymphoma (PTCL) in patients intolerant to standard chemotherapy (China)

China, Oct. 15 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicenter, single-arm, open-label clinical efficacy observation study of chidamide in combination with azacitidine, prednisone, cyclophosphamide, and thalidomide for the treatment of peripheral T-cell lymphoma (PTCL) in patients intolerant to standard chemotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134410

Registration Time: 2026/10/14

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337504

Published by HT Digital Content Services w...